※ May 28, 2024, Jiangsu Genscend Biopharma Co., Ltd. was established.
※ On June 7, 2024, Project GS101 was officially initiated.
※ On January 6, 2025, Project GS301 was officially initiated.
※ On November 8, 2025, the IND application for Project GS101 was accepted by the CDE.
※ On October 21, 2025, the Shanghai Branch was established.
※ On December 10, 2025, the company was officially renamed to Jiangsu Genscend Biopharma Co., Ltd.
※ The company announces that the Investigational New Drug application for its self-developed dupilumab biosimilar, GS101, has received implicit approval from the Center for Drug Evaluation of the National Medical Products Administration. The approval was recorded on January 13, 2026 (Acceptance No.: CXSL2500955). The proposed indication is the treatment of atopic dermatitis.
Address:
· Building 1, No. 907 Yaocheng Avenue, Hailing District, Taizhou City, Jiangsu Province
· Shanghai Branch : Room 1808, Building A, No.100 Zunyi Road, Changning District, Shanghai
Copyright © 2025 江苏景行生物医药有限公司 All Rights Reserved.
苏ICP备2026007812号.
